CytoMed Therapeutics
- Country
- 🇸🇬Singapore
- Ownership
- -
- Employees
- 34
- Market Cap
- $18.3M
- Introduction
CytoMed Therapeutics Ltd. is a biopharmaceutical company, which engages in the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy, and undertaking the research and development of immune cell and stem cell-based therapy. It operates through the Malaysia and Singapore geographical segments. The company was founded by Chee Kong Choo on March 9, 2018 and is headquartered in Singapore.
Clinical Trials
2
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA)
- Conditions
- MalignancyRelapsed CancerCancerRefractory Cancer
- Interventions
- Biological: Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- CytoMed Therapeutics Pte Ltd
- Target Recruit Count
- 12
- Registration Number
- NCT05302037
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour
- Conditions
- Prostate CancerColorectal CancerTriple Negative Breast CancerGastric CancerSarcomaNasopharyngeal Carcinoma
- First Posted Date
- 2019-09-27
- Last Posted Date
- 2019-09-27
- Lead Sponsor
- CytoMed Therapeutics Pte Ltd
- Target Recruit Count
- 10
- Registration Number
- NCT04107142
- Locations
- 🇲🇾
Landmark Medical Centre, Johor Bahru, Johor, Malaysia
News
CytoMed Therapeutics Advances Novel CAR Gamma Delta T Cell Therapy to Phase I Dose Level 2
CytoMed Therapeutics successfully completed dose level 1 of its first-in-human Phase I ANGELICA trial for CTM-N2D therapy in four late-stage cancer patients.
TC Biopharm Leads Gamma Delta T Cell Therapy Development with Over 25 Clinical Programs Worldwide
TC Biopharm's OmnImmune is advancing through a pivotal Phase 2/3 trial for acute myeloid leukemia, representing one of the most advanced gamma delta T cell therapies globally.
CytoMed and SunAct Partner to Advance Gamma Delta T-Cell Therapy for Solid Tumors in India
CytoMed Therapeutics and SunAct Cancer Institute collaborate to evaluate allogeneic gamma delta T cells for solid tumor treatment in a Phase 2 trial.
CytoMed's ANGELICA Trial: Revolutionizing Cancer Treatment with Off-the-Shelf Gamma-Delta T Cell Therapy
CytoMed Therapeutics launches the ANGELICA trial, utilizing donor-derived gamma-delta T cells to target solid tumors resistant to standard treatments.
CytoMed Therapeutics Initiates Phase I Trial of CTM-ONC in Solid Tumors
CytoMed Therapeutics has begun its Phase I ANGELICA trial, evaluating CTM-ONC in patients with advanced solid tumors.
CytoMed Therapeutics' ANGELICA Trial Receives Approval for Phase I Study in Advanced Cancers
CytoMed Therapeutics has received full approval for its Phase I ANGELICA trial, evaluating allogeneic CAR-T cell therapy in advanced cancers.
Canadian-Developed CAR T-Cell Therapy Targeting CD22 Heads to Clinical Trials
The National Research Council of Canada has developed a novel CAR T-cell therapy targeting the CD22 protein on B-cell leukemia and lymphoma cells, offering hope for patients who failed previous CD19-targeted treatments.